摘要
背景:尽管可以转录多达90%的真核基因组,但只有1-2%的所得转录本编码蛋白质,而其余的可以分类为非编码RNA(ncRNA),其主要由长ncRNA(lncRNAs)组成)和小ncRNAs。总体来说,他们被建议针对基因组中的特定区域,并在许多重要的生物过程中发挥多方面的作用。 总结:最近的证据表明,ncRNAs在脑中大量表达,其中许多在神经障碍中被异常调节。然而,它们在相关生理和病理过程中的功能相关性尚未得到充分的了解。因此,阐明ncRNA在脑中的作用将大大增强目前对神经发育的认识,最终导致治疗神经疾病的新策略。在本报告中,我们回顾了lncRNAs和各种类型的小ncRNAs在脑发育和神经障碍中的结构和机制。 观点:我们希望对这些ncRNA的广泛研究将揭示和表征脑中的新型分子电路,并促进为患有神经障碍的人开发基于RNA的治疗剂。
关键词: lncRNA,miRNA,piRNA,碱基配对,脑发育,神经障碍。
Current Medicinal Chemistry
Title:Non-Coding RNA in Brain Development and Disorder
Volume: 24 Issue: 18
关键词: lncRNA,miRNA,piRNA,碱基配对,脑发育,神经障碍。
摘要: Background: Although up to 90% of the eukaryotic genome can be transcribed, only 1-2% of the resultant transcripts encode for proteins, while the remaining can be classified as non-coding RNAs (ncRNAs) which mostly consist of long ncRNAs (lncRNAs) and small ncRNAs. In overall, they have been suggested to target specific regions in the genome and play multi-faceted roles in many important biological processes.
Summary: Recent evidence has shown that ncRNAs are abundantly expressed in the brain and many of them are aberrantly regulated in neural disorders. Yet their functional relevance in related physiological and pathological processes has not been adequately understood. Thus, the elucidation of the role of ncRNAs in the brain would greatly enhance the current understanding of neural development and ultimately lead to novel strategies to treat neural diseases. In this report, we reviewed the structure and mechanism of lncRNAs and various classes of small ncRNAs in brain development and neural disorders. Perspective: We hope that extensive studies of these ncRNAs would unravel and characterize novel molecular circuits in the brain, and facilitate the development of RNA-based therapeutics for people suffering from neural disorders.Export Options
About this article
Cite this article as:
Non-Coding RNA in Brain Development and Disorder, Current Medicinal Chemistry 2017; 24 (18) . https://dx.doi.org/10.2174/0929867324666170124151436
DOI https://dx.doi.org/10.2174/0929867324666170124151436 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Amplicons as Vaccine Vectors
Current Gene Therapy The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Editorial (Thematic Issue: Self-Assembled Organic Nanostructures in Medicinal Chemistry: Advances and Applications)
Current Topics in Medicinal Chemistry GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets Drugs Interfering with Apoptosis in Breast Cancer
Current Pharmaceutical Design The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Current Molecular Medicine Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Optimal Saturated Neuropilin-1 Expression in Normal Tissue Maximizes Tumor Exposure to Anti-Neuropilin-1 Monoclonal Antibody
Anti-Cancer Agents in Medicinal Chemistry Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) A Unique Intracellular, Extracellular and Transmembrane Circulation of Potassium Ions in the Auditory Inner Ear as an Anticarcinogenic Principle? Part 1
Inflammation & Allergy - Drug Targets (Discontinued) Heterodimeric Amino Acid Transporters: Molecular Biology and Pathological and Pharmacological Relevance
Current Drug Metabolism Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Dual Targeting of Autophagy and NF-κB Pathway by PPARγ Contributes to the Inhibitory Effect of Demethoxycurcumin on NLRP3 Inflammasome Priming
Current Molecular Pharmacology AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Potentials and Challenges of Active Targeting at the Tumor Cells by Engineered Polymeric Nanoparticles
Current Pharmaceutical Biotechnology